FBC Holding, Inc. (FBCD) Acquires Mushroom Madness to Accelerate Entry Into Explosive Mushroom Wellness Market

Rhea-AI Summary

FBC Holding (OTC:FBCD) announced it has acquired Mushroom Madness via a stock-based transaction to accelerate entry into the mushroom wellness market on December 10, 2025.

The company highlighted mushroom product lines focused on vegan, adaptogen-infused formulations for energy, focus, stress relief, and immune support, and said incorporation in Oregon provides a regulatory runway for therapeutic and clinical opportunities. The release cited industry projections including $22.3B by 2030 at a 9.3%+ CAGR and a combined $34B+ by 2033 global market estimate, and described planned scaling of manufacturing, new SKUs, retail and subscription channels, and national online expansion.

Positive

• Acquisition completed via stock-based transaction
• Industry forecast: $22.3B by 2030 at 9.3%+ CAGR
• Company cites $34B+ combined market by 2033
• Oregon incorporation provides regulatory runway for therapeutic products

Negative

• None.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, FBCD declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Functional mushroom market: $22.3 billion Functional mushroom CAGR: 9.3% Legal & functional mushrooms: $34+ billion +5 more

8 metrics

Functional mushroom market $22.3 billion Projected global functional mushroom industry size by 2030

Functional mushroom CAGR 9.3% Projected CAGR for global functional mushroom industry

Legal & functional mushrooms $34+ billion Projected combined annual global revenue by 2033

U.S. market share increase 400% Projected U.S. mushroom market share increase from 2025–2030

Nootropics/adaptogens growth 14% Annual rise in consumer demand for nootropics and adaptogens

Donation per item $5 Per Formrunner Apparel item donated to Kerr County Flood Relief Fund

Relief campaign end date August 15, 2025 End date for Kerr County Flood Relief donation campaign

Streetwear CAGR 11.8% Projected CAGR of global streetwear market cited in prior news

Market Reality Check

Price: $0.0001 Vol: Volume 114,500 is well be...

low vol

$0.0001 Last Close

Volume Volume 114,500 is well below the 20-day average of 1,627,767, suggesting limited pre-news positioning. low

Technical Shares at $0.00015 are below the 200-day MA (ma_200_position: below), near the 52-week low of $0.00015 and 25% under the $0.0002 52-week high.

Peers on Argus

Peers show mixed moves (e.g., IVDN -5.35%, YUKA +2.5%, CCRRF -31.03%), with no c...

Peers show mixed moves (e.g., IVDN -5.35%, YUKA +2.5%, CCRRF -31.03%), with no consistent direction and no momentum flags, indicating this acquisition is likely a stock-specific catalyst rather than a sector trend.

Historical Context

3 past events · Latest: Jul 24 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Jul 24	Charity initiative	Positive	+100.0%	Charitable campaign tied to Formrunner sales and flood relief donations.
Jul 22	Brand collaboration	Positive	+100.0%	Strategic collaboration with dzerted to expand streetwear presence at Studio 22.
Jul 15	Shareholder update	Positive	+0.0%	Shareholder letter outlining streetwear market outlook and multi-channel strategy.

Pattern Detected

Recent upbeat corporate news and brand initiatives have often coincided with sharp positive reactions, but not consistently so, suggesting event-driven spikes rather than a stable trend.

Recent Company History

Over the last few months, FBCD focused on streetwear and brand-building around Formrunner Apparel. In July 2025, a charitable campaign tied to Texas flood relief and a strategic collaboration with streetwear brand dzerted each saw +100% next-day moves. A broader shareholder letter on Jul 15, 2025 outlining e-commerce and flagship store expansion had a flat price reaction. Today’s mushroom wellness acquisition reflects a strategic pivot from apparel-focused growth to functional wellness and psychedelic-adjacent opportunities.

Market Pulse Summary

This announcement details FBCD’s acquisition of Mushroom Madness via a stock-based deal, marking a p...

Analysis

This announcement details FBCD’s acquisition of Mushroom Madness via a stock-based deal, marking a pivot from apparel into functional and potentially psychedelic mushroom wellness. Management cites markets projected above $22.3 billion and a combined $34+ billion by 2033, with strong demand for nootropics and adaptogens. Historically, upbeat brand and collaboration news sometimes produced sharp moves, but not uniformly. Investors may watch how quickly FBCD scales SKUs, builds recurring revenue, and integrates this new category with its existing brand ecosystem.

Key Terms

adaptogen-infused, adaptogenic, psychedelic mushroom sector, nootropics, +3 more

7 terms

adaptogen-infused medical

"specializing in vegan, adaptogen-infused mushroom formulations."

A label indicating a product contains one or more plant- or mushroom-based ingredients marketed as adaptogens—substances promoted to help the body cope with stress, fatigue or recovery. For investors, the term signals a product positioned to tap consumer wellness trends and potentially command higher prices, but it also brings scientific uncertainty and regulatory or labeling risk—like adding a trendy spice to a recipe that may boost sales but doesn’t guarantee better results.

adaptogenic medical

"vegan, premium-grade, adaptogenic mushroom products designed for daily energy"

Adaptogenic describes herbs, mushrooms or supplements marketed as helping the body cope with physical or mental stress and restore balance, like a shock absorber or thermostat for the body’s responses. It matters to investors because products labeled adaptogenic can drive consumer demand and premium pricing, but claims often face varying levels of scientific support and regulatory scrutiny, which can affect sales, labeling risk and company valuation.

psychedelic mushroom sector medical

"evaluating strategic entry into the psychedelic mushroom sector"

The psychedelic mushroom sector comprises companies and research groups developing, producing, or supporting products and therapies derived from psilocybin-containing mushrooms, including medical research, cultivation, formulation, and clinical services. Investors watch this sector because its value hinges on clinical trial results, shifting laws, and potential new treatments for mental health; think of it like an early-stage frontier industry where breakthroughs or regulatory setbacks can rapidly swing company fortunes.

nootropics medical

"A surge in consumer demand for nootropics and adaptogens, rising 14% annually"

Nootropics are substances taken to boost mental performance—such as memory, focus, or alertness—and can range from herbal supplements and vitamins to prescription drugs. For investors they matter because consumer demand, scientific evidence, safety concerns, and regulatory scrutiny affect product sales, company valuations, and potential liability much like how a new fitness trend can drive growth for sports brands but also invite oversight if claims don’t hold up.

CAGR financial

"projected to surge past $22.3 billion by 2030, fueled by a 9.3%+ CAGR"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

subscription-based recurring revenue financial

"Subscription-based recurring revenue models (a core driver in consumer wellness valuations)"

Revenue that a company earns on an ongoing basis from customers who pay regularly for a service or product, like a magazine subscription or monthly phone plan. Investors value it because predictable, repeat payments make future sales easier to forecast, support steadier cash flow, and often indicate loyal customers, which can increase a company's growth prospects and make its stock less risky compared with one-time sales.

SKUs technical

"plans to scale Mushroom Madness' manufacturing volume, launch new SKUs"

SKUs, or stock keeping units, are unique codes used to identify individual products in a company's inventory. They help businesses track how many items they have, sell, or need to restock, similar to how a library assigns specific numbers to books for easy organization. For investors, SKUs provide insight into a company's product lineup and sales performance, which can influence financial health and growth prospects.

AI-generated analysis. Not financial advice.

With the global functional mushroom industry projected to surge past $22.3 billion by 2030, fueled by a 9.3%+ CAGR, FBCD's strategic acquisition positions the company at the forefront of one of the fastest-growing wellness sectors in America - especially as Oregon leads the nation in legalized therapeutic mushroom innovation.

SCOTTSDALE, ARIZONA / ACCESS Newswire / December 10, 2025 / FBC Holding, Inc. (OTCID:FBCD) is thrilled to announce the acquisition of Mushroom Madness, a rapidly expanding wellness brand specializing in vegan, adaptogen-infused mushroom formulations. The acquisition was completed through a stock-based transaction, allowing both organizations to align long-term value and accelerate market growth together.

This acquisition marks a pivotal advancement in FBCD's expansion into high-growth consumer wellness markets that are seeing unprecedented demand from health-driven consumers, athletes, creatives, and professionals striving for natural performance solutions. Building on this momentum, the company is actively evaluating strategic entry into the psychedelic mushroom sector, a market widely projected to become one of the most transformative wellness categories of the decade.

Mushroom Madness, located online at http://mushroommadness.shop, produces a full suite of vegan, premium-grade, adaptogenic mushroom products designed for daily energy, cognitive focus, stress relief, and immune support. Every product is formulated with high-quality natural ingredients, aligning with FBCD's broader mission of delivering science-backed wellness solutions with mass-market potential.

A Perfect Match in a Booming Legal Landscape

FBCD's expansion into mushrooms is particularly strategic given that the company is incorporated in Oregon - one of the nation's only states where therapeutic mushrooms have been legalized and regulated. This regulatory foundation provides a powerful runway for product innovation, wholesale licensing, clinical collaborations, and potentially even experiential wellness offerings as state-level frameworks evolve.

Industry analysts expect legal and functional mushroom categories combined to exceed:

• $34+ billion in annual global revenue by 2033

• A projected U.S. market share increase of 400% from 2025-2030

• A surge in consumer demand for nootropics and adaptogens, rising 14% annually

This acquisition situates FBCD at the center of a market experiencing exponential growth with low competition and massive runway.

CEO Statement

"Acquiring Mushroom Madness is a transformational moment for FBCD," said CEO Lisa Nelson. "The mushroom wellness category is not only expanding rapidly, but it aligns perfectly with consumer demand for clean, vegan, plant-powered products. With Oregon leading the nation in therapeutic innovation, we are now positioned to develop revenue streams that most companies in our space cannot touch. This acquisition accelerates our mission and opens the door to something much bigger than supplements-it opens the door to an entirely new era for FBCD."

New Revenue Opportunities Ahead

The acquisition opens a robust set of avenues for immediate and long-term monetization, including:

• Retail & wholesale distribution into wellness stores, gyms, spas, coffee shops, and health boutiques

• Subscription-based recurring revenue models (a core driver in consumer wellness valuations)

• Co-branded product collaborations within FBCD's expanding brand ecosystem

• Future therapeutic applications made possible through Oregon's regulatory framework

• National online expansion leveraging FBCD's strong digital marketing infrastructure

FBCD also plans to scale Mushroom Madness' manufacturing volume, launch new SKUs, and strategically target the booming adaptogen space with competitive pricing, advanced formulations, and high-margin product lines.

About Mushroom Madness

Mushroom Madness produces premium functional mushroom supplements using only vegan, cruelty-free, high-quality adaptogens aimed at improving mental clarity, reducing stress, boosting natural energy, and supporting immune health. Products are available at http://mushroommadness.shop.

About FBC Holding, Inc. (FBCD)

FBC Holding, Inc. is a diversified holding company focused on developing consumer brands, wellness products, and high-growth retail concepts. With strategic positioning in Oregon and operational presence in Arizona, the company is expanding rapidly across multiple emerging markets including wellness, adaptogens, supplements, and consumer lifestyle products.

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Lisa Nelson
Email: lisa@formrunnerapparel.com
Phone 480-516-3394

SOURCE: FBC Holding, Inc.

View the original press release on ACCESS Newswire

FAQ

What did FBC Holding (FBCD) announce on December 10, 2025?

FBCD announced it acquired Mushroom Madness in a stock-based transaction to expand into the mushroom wellness market.

How large is the mushroom market cited by FBC Holding (FBCD)?

The company cited a $22.3B global functional mushroom market by 2030 and a $34B+ combined estimate by 2033.

What products does Mushroom Madness provide under FBCD?

Mushroom Madness offers vegan, adaptogen-infused mushroom formulations for energy, cognitive focus, stress relief, and immune support.

Why is FBCD's Oregon incorporation important for the Mushroom Madness deal?

FBCD said Oregon's legalized therapeutic mushroom framework provides a regulatory runway for product innovation and clinical collaborations.

Will FBCD change Mushroom Madness distribution after the acquisition?

FBCD plans to scale manufacturing, launch new SKUs, expand retail and wholesale channels, and pursue national online growth.

Did FBCD disclose the transaction price for the Mushroom Madness acquisition?

The announcement states the deal was stock-based but does not disclose a monetary transaction price.